Literature DB >> 21540335

Chemical and mechanistic toxicology evaluation of exon skipping phosphorodiamidate morpholino oligomers in mdx mice.

Peter Sazani1, Kirk P Van Ness, Doreen L Weller, Duane Poage, Keith Nelson, And Stephen B Shrewsbury.   

Abstract

AVI-4658 is a phosphorodiamidate morpholino oligomer (PMO) designed to induce skipping of dystrophin exon 51 and restore its expression in patients with Duchenne muscular dystrophy (DMD). Preclinically, restoration of dystrophin in the dystrophic mdx mouse model requires skipping of exon 23, achieved with the mouse-specific PMO, AVI-4225. Herein, we report the potential toxicological consequences of exon skipping and dystrophin restoration in mdx mice using AVI-4225. We also evaluated the toxicological effects of AVI-4658 in both mdx and wild-type mice. In both studies, animals were dosed once weekly for 12 weeks up to the maximum feasible dose of 960 mg/kg per injection. Both AVI-4658 and AVI-4225 were well-tolerated at all doses. Findings in AVI-4225-treated animals were generally limited to mild renal tubular basophilia/vacuolation, without any significant changes in renal function and with evidence of reversing. No toxicity associated with the mechanism of action of AVI-4225 in a dystrophic animal was observed.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21540335     DOI: 10.1177/1091581811403504

Source DB:  PubMed          Journal:  Int J Toxicol        ISSN: 1091-5818            Impact factor:   2.032


  15 in total

1.  Morpholino treatment improves muscle function and pathology of Pitx1 transgenic mice.

Authors:  Sachchida Nand Pandey; Yi-Chien Lee; Toshifumi Yokota; Yi-Wen Chen
Journal:  Mol Ther       Date:  2013-11-14       Impact factor: 11.454

2.  Development of novel bioanalytical methods to determine the effective concentrations of phosphorodiamidate morpholino oligomers in tissues and cells.

Authors:  Frederick J Schnell; Stacy L Crumley; Dan V Mourich; Patrick L Iversen
Journal:  Biores Open Access       Date:  2013-02

Review 3.  Gene therapies that restore dystrophin expression for the treatment of Duchenne muscular dystrophy.

Authors:  Jacqueline N Robinson-Hamm; Charles A Gersbach
Journal:  Hum Genet       Date:  2016-08-20       Impact factor: 4.132

4.  Targeting KIT by frameshifting mRNA transcripts as a therapeutic strategy for aggressive mast cell neoplasms.

Authors:  Douglas B Snider; Greer K Arthur; Guido H Falduto; Ana Olivera; Lauren C Ehrhardt-Humbert; Emmaline Smith; Cierra Smith; Dean D Metcalfe; Glenn Cruse
Journal:  Mol Ther       Date:  2021-08-08       Impact factor: 11.454

5.  Systemic antisense therapeutics inhibiting DUX4 expression ameliorates FSHD-like pathology in an FSHD mouse model.

Authors:  Ngoc Lu-Nguyen; Alberto Malerba; Shan Herath; George Dickson; Linda Popplewell
Journal:  Hum Mol Genet       Date:  2021-07-09       Impact factor: 6.150

6.  Long-term efficacy of systemic multiexon skipping targeting dystrophin exons 45-55 with a cocktail of vivo-morpholinos in mdx52 mice.

Authors:  Yusuke Echigoya; Yoshitsugu Aoki; Bailey Miskew; Dharminder Panesar; Aleksander Touznik; Tetsuya Nagata; Jun Tanihata; Akinori Nakamura; Kanneboyina Nagaraju; Toshifumi Yokota
Journal:  Mol Ther Nucleic Acids       Date:  2015-02-03       Impact factor: 10.183

7.  The use of urinary and kidney SILAM proteomics to monitor kidney response to high dose morpholino oligonucleotides in the mdx mouse.

Authors:  Aiping Zhang; Kitipong Uaesoontrachoon; Conner Shaughnessy; Jharna R Das; Sree Rayavarapu; Kristy J Brown; Patricio E Ray; Kanneboyina Nagaraju; John N van den Anker; Eric P Hoffman; Yetrib Hathout
Journal:  Toxicol Rep       Date:  2015

8.  Elusive sources of variability of dystrophin rescue by exon skipping.

Authors:  Maria Candida Vila; Margaret Benny Klimek; James S Novak; Sree Rayavarapu; Kitipong Uaesoontrachoon; Jessica F Boehler; Alyson A Fiorillo; Marshall W Hogarth; Aiping Zhang; Conner Shaughnessy; Heather Gordish-Dressman; Umar Burki; Volker Straub; Qi Long Lu; Terence A Partridge; Kristy J Brown; Yetrib Hathout; John van den Anker; Eric P Hoffman; Kanneboyina Nagaraju
Journal:  Skelet Muscle       Date:  2015-12-01       Impact factor: 4.912

9.  Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy.

Authors:  Jerry R Mendell; Nathalie Goemans; Linda P Lowes; Lindsay N Alfano; Katherine Berry; James Shao; Edward M Kaye; Eugenio Mercuri
Journal:  Ann Neurol       Date:  2016-01-08       Impact factor: 10.422

10.  Peptide-mediated Cell and In Vivo Delivery of Antisense Oligonucleotides and siRNA.

Authors:  Peter Järver; Thibault Coursindel; Samir El Andaloussi; Caroline Godfrey; Matthew Ja Wood; Michael J Gait
Journal:  Mol Ther Nucleic Acids       Date:  2012-06-12       Impact factor: 10.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.